Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer’s Disease, at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Provided By GlobeNewswire
Last update: Oct 30, 2024
Dose-dependent increase in neuroprotective APOE2 expression in all participants with ongoing durability at 12 months
Consistent reductions across CSF tau biomarkers and tau PET in majority of participants
Read more at globenewswire.com3.89
-0.14 (-3.47%)
Find more stocks in the Stock Screener
LXEO Latest News and Analysis
3 days ago - ChartmillStay updated with the stocks that are on the move in today's pre-market session.As the US market prepares to open on Thursday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
